Pfizer

For 175 years, Pfizer has been a trusted partner in healthcare – discovering, developing, and delivering medical breakthroughs to prevent, treat, and cure some of the world’s most vexing conditions and diseases.

Pfizer's EU Policy team partners with EU policy-makers and other stakeholders, driven by our purpose: Breakthroughs that change patients’ lives.

https://www.pfizereupolicy.eu/

Close
Pfizer

Featured
The time is now: Combatting Antimicrobial Resistance with Transferable Exclusivity Vouchers Partner Content
The time is now: Combatting Antimicrobial Resistance with Transferable Exclusivity Vouchers
20 Nov EU Institutions
by Andrea Chiarello
The EU has a once-in-a-generation window of opportunity to implement an effective pull incentive for combating AMR.
Articles
Unlocking innovation in the fight against cancer Partner Content
09 Oct
Unlocking innovation in the fight against cancer
What more can Europe do to unlock access to new medicines and treatments that are bringing fresh hope to cancer patients? The Parliament sat down with Dr Kandeepan Ganeshalingam, Vice President Oncology International Medical Affairs at Pfizer, to find out why innovation could be key to helping people live longer and live better
Industrial policy and what it means for the healthcare sector Partner Content
05 Jul
Industrial policy and what it means for the healthcare sector
Putting a strong focus on competitiveness and industrial policy is a vital lesson Europe must learn from its recent challenges
Time for a New Model to Tackle Cancer Care Disparities Partner Content
29 Jun
Time for a New Model to Tackle Cancer Care Disparities
Berfu Yaziyurt of Pfizer and MEP Bartosz Arłukowicz call on the EU to tackle disparities in cancer care at a European level, using a multidisciplinary model.
Rare Diseases: Time for Innovation Partner Content
27 Jun
Rare Diseases: Time for Innovation
Pfizer's Reda Guiha and MEP Maria da Graça Carvalho want to see the EU do more to deliver on its promise for people living with a rare disease, by supporting research in new medical innovations.
How do we solve the rare disease crisis? Partner Content
27 May
How do we solve the rare disease crisis?
Pfizer often made the headlines over the past year after mobilising their scientific expertise and manufacturing capabilities to respond to the COVID-19 pandemic. Reda Guiha, Regional President for Rare Disease at Pfizer, argues that the same sense of urgency and public-private sector collaboration that brought vaccines to patients within a year should be applied to other areas of critical unmet medical need, such as rare disease.